Trial treatments and follow-up
ADVERSE EVENTS
The trial drugs were discontinued prematurely in 8 patients (18.6%) in the metformin group, 32 patients (61.5%) in the donepezil group and 5 patients (10.4%) in the placebo group. The main reason for treatment withdrawal was related to drug adverse events. Pill count adherence showed at least 80% compliance in 66.7% of the placebo group, 58.1% for the metformin group and 32.7% in the donepezil group. Six patients (13.9%) in the metformin group and three patients (5.8%) in the donepezil group took half of the prescribed dose of metformin (1000 mg) and donepezil (5 mg). Only one patient (donepezil group) was loss to follow-up.